Efficacy and tolerability of mirabegron in female patients with overactive bladder symptoms after surgical treatment for stress urinary incontinence

Conclusion Mirabegron is safe, effective and tolerable in the long-term treatment of females with OAB symptoms after surgery for s tress urinary incontinence.
Source: International Braz J Urol - Category: Urology & Nephrology Source Type: research

Related Links:

Authors: Elbaset MA, Taha DE, El-Hefnawy AS, Zahran MH, Shokeir AA Abstract PURPOSE: To evaluate the efficacy and safety of re-treatment with anticholinergics on refractory idiopathic overactive bladder (OAB) previously treated with intravesical botulinum neurotoxin type A (BTX-A) injections. METHODS: One hundred patients were initially managed by intravesical injections of 100 IU of BTX-A. After the effects of BTX-A faded, patients were randomized into 2 groups: group A patients received solifenacin (10 mg) for 12 weeks (study group), while group B patients received placebo treatment for 12 weeks (control grou...
Source: International Neurourology Journal - Category: Urology & Nephrology Tags: Int Neurourol J Source Type: research
Publication date: November–December 2019Source: Journal of Minimally Invasive Gynecology, Volume 26, Issue 7, SupplementAuthor(s): L Zhu, Y ZhangStudy ObjectiveTo evaluate the long-term safety and effectiveness of inside–out transobturator tape (tension-free vaginal tape-obturator, TVT-O) for the treatment of stress urinary incontinence (SUI).DesignA prospective cohort study. The duration of follow-up was 12years.SettingCenter of obstetrics and gynecology in a tertiary-care hospital.Patients or ParticipantsBetween August 2004 and August 2006, 87 consecutive patients with SUI who underwent TVT-O were enrolled in...
Source: Journal of Minimally Invasive Gynecology - Category: OBGYN Source Type: research
Medtronic has filed for FDA approval for its InterStim Micro neurostimulator and the accompanying InterStim SureScan MRI leads. The rechargeable device delivers sacral neuromodulation therapy to treat conditions such as overactive bladder, fecal inco...
Source: Medgadget - Category: Medical Devices Authors: Tags: Neurology Neurosurgery Radiology Rehab Source Type: blogs
Conditions:   Overactive Bladder;   Urinary Incontinence Interventions:   Device: Microcurrents;   Device: Placebo Microcurrents Sponsor:   University of Las Palmas de Gran Canaria Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
This study investigated the effects of a low ‐frequency home‐based incontinence therapy device on quality of life (QoL) and urinary symptoms in women with urinary incontinence. From May 2017 to February 2018, 34 patients, aged ≥ 20 years, with involuntary urine leakage>2 times/week, were recruited to this study. Patients with severe pelvic organ prolapse, pregnancy, virgin status, and psychological problems were excluded. The incontinence home ‐care device treatments were administered in 12‐minute sessions, twice daily for 8 weeks. Simultaneously, hyperthermic conditions of 35°C to 40...
Source: LUTS: Lower Urinary Tract Symptoms - Category: Urology & Nephrology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Medtronic and Axonics are getting ready to square off in sacral neuromodulation, a fast-growing market that was monopolized by Medtronic until a month ago. Last month, Axonics won FDA approval to market its implantable rechargeable sacral neuromodulation (r-SNM) device for the treatment of fecal incontinence, and the company is expected to get FDA approval for overactive bladder and urinary retention any time now. The fecal incontinence approval includes the claim of a 15-year functional life and the ability of patients to undergo full-body MRI scans without the necessity of having the device explanted. Medtron...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news
CONCLUSION: Our externally validated machine learning prediction model can predict anticholinergic treatment failure during the standard 3-month treatment trial period with greater than 80% accuracy. The model can be accessed at https://oabweb.herokuapp.com/app/pre/. PMID: 31599833 [PubMed - as supplied by publisher]
Source: Obstetrics and Gynecology - Category: OBGYN Authors: Tags: Obstet Gynecol Source Type: research
AbstractIntroductionOveractive bladder (OAB) is a common condition, increasing with age and affecting quality of life. While numerous OAB drugs are available, persistence is low. We evaluated evidence published since 2012 to determine if newer drugs provided better efficacy and harm profiles.MethodsWe searched MEDLINE and the Cochrane Library from 2012 to September 2018 using terms for included drugs and requested information from manufacturers of included drugs. We performed dual review of all systematic review processes, evaluated study quality, and conducted meta-analyses using random effects models.ResultsIn addition t...
Source: International Urogynecology Journal - Category: OBGYN Source Type: research
ConclusionPersistence and adherence to OAB medication may be suboptimal. HCPs might be able to improve persistence and adherence by fostering realistic treatment expectations and scheduling regular medication reviews. These measures may help optimise patient care and support more adherent behaviours, thus minimising the impact of undertreated OAB on patient quality of life.FundingInnovate UK and Astellas Pharma Europe Ltd (APEL).
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
Abstract PURPOSE: Recurrent bacterial cystitis is a common infection in women and there are concerns about its antibiotic therapy. Platelet rich plasma has antimicrobial and tissue repairing effects. We investigated the effect of platelet rich plasma as an intravesical therapy to prevent recurrence of bacterial cystitis. Materials and Methods: Thirty women with a history of recurrent bacterial cystitis were randomly assigned into two groups: 1) platelet rich plasma and 2) control groups. The first group received 10 mL of platelet rich plasma with intravesical instillation plus 40 mL of normal saline. The cont...
Source: Urology Journal - Category: Urology & Nephrology Authors: Tags: Urol J Source Type: research
More News: Cardiology | Heart | Incontinence | Overactive Bladder | Overactive Bladder Syndrome | Study | Urology & Nephrology | VESIcare